Phaseline

Companies › enGene

enGene: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EG-70 (detalimogene voraplasmid)
Viral vector-delivered IL-12 gene therapy for intravesical bladder instillation
IL12Phase 1Superficial Bladder CancerApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04752722EG-70 (detalimogene voraplasmid)Phase 1Superficial Bladder CancerOncologyApr 2028

From the company's SEC filings

Cash and short-term investments of $266m on 2026-07-31; operating cash outflow about $105m a year; runway about 30 months at that burn, to Feb 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IL12 (1)

Companies with the same targets

Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA Inovio Pharmaceuticals Trogenix

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.